Real-world efficacy and safety of trifluridine/tipiracil plus bevacizumab for patients with metastatic colorectal cancer refractory to standard therapies

被引：0
|
作者：
Martinez Lago, N. [1 ]
Alonso de Castro, B. [2 ]
Varela Ponte, R. [3 ]
Reboredo Rendo, C. [2 ]
Gomez-Randulfe Rodriguez, M. [2 ]
Grana Suarez, B. [4 ]
de la Camara Gomez, J. [2 ]
Mateos Salvador, M. [2 ]
Busto Fernandez, F. [2 ]
Calleja Chucla, T. [2 ]
Reboredo-Lopez, M. [2 ]
机构：
[1] Complejo Hosp Univ, La Coruna, Spain
[2] Univ Hosp A Coruna, La Coruna, Spain
[3] Complejo Hosp Univ Santiago, Santiago De Compostela, A Coruna, Spain
[4] Complejo Hosp Univ A Coruna, Inst Invest Biomed INIBIC, La Coruna, Spain
来源：
ANNALS OF ONCOLOGY | 2021年 / 32卷
关键词：
D O I：
10.1016/j.annonc.2021.05.086
中图分类号：
R73 [肿瘤学];
学科分类号：
100214 ;
摘要：
P-31
引用
收藏
页码：S106 / S107
页数：2
相关论文
共 50 条
  • [1] Efficacy, safety and prognostic factors in patients with refractory metastatic colorectal cancer treated with trifluridine/tipiracil plus bevacizumab in a real-world setting
    Martinez-Lago, Nieves
    Calleja Chucla, Teresa
    Alonso De Castro, Beatriz
    Varela Ponte, Rafael
    Reboredo Rendo, Cristina
    Gomez-Randulfe Rodriguez, Martin Igor
    Silva Diaz, Sofia
    Grana Suarez, Begona
    de la Camara Gomez, Juan
    Busto Fernandez, Fernando
    Mateos Salvador, Maria
    Reboredo Lopez, Margarita
    SCIENTIFIC REPORTS, 2022, 12 (01)
  • [2] Real-World Activity and Safety of Trifluridine-Tipiracil Plus Bevacizumab Therapy in Patients with Refractory Metastatic Colorectal Cancer
    Gianluca Arrichiello
    Alessandra Perrone
    Stefania Napolitano
    Giulia Martini
    Vincenzo De Falco
    Pasquale Incoronato
    Maria Maddalena Laterza
    Gaetano Facchini
    Vincenzo Famiglietti
    Valeria Nacca
    Fernando Paragliola
    Rossella Napolitano
    Gabriella Suarato
    Antonella Nicastro
    Erika Martinelli
    Davide Ciardiello
    Fortunato Ciardiello
    Teresa Troiani
    Targeted Oncology, 2022, 17 : 635 - 642
  • [3] Real-World Activity and Safety of Trifluridine-Tipiracil Plus Bevacizumab Therapy in Patients with Refractory Metastatic Colorectal Cancer
    Arrichiello, Gianluca
    Perrone, Alessandra
    Napolitano, Stefania
    Martini, Giulia
    De Falco, Vincenzo
    Incoronato, Pasquale
    Laterza, Maria Maddalena
    Facchini, Gaetano
    Famiglietti, Vincenzo
    Nacca, Valeria
    Paragliola, Fernando
    Napolitano, Rossella
    Suarato, Gabriella
    Nicastro, Antonella
    Martinelli, Erika
    Ciardiello, Davide
    Ciardiello, Fortunato
    Troiani, Teresa
    TARGETED ONCOLOGY, 2022, 17 (06) : 635 - 642
  • [4] Efficacy, safety and prognostic factors in patients with refractory metastatic colorectal cancer treated with trifluridine/tipiracil plus bevacizumab in a real-world setting
    Nieves Martínez-Lago
    Teresa Calleja Chucla
    Beatriz Alonso De Castro
    Rafael Varela Ponte
    Cristina Reboredo Rendo
    Martin Igor Gomez-Randulfe Rodriguez
    Sofia Silva Diaz
    Begoña Graña Suarez
    Juan de la Cámara Gomez
    Fernando Busto Fernández
    María Mateos Salvador
    Margarita Reboredo Lopez
    Scientific Reports, 12
  • [5] Multi-institutional analysis of real-world activity and safety of trifluridine/tipiracil plus bevacizumab in patients with refractory metastatic colorectal cancer
    Arrichiello, G.
    Martinelli, E.
    Troiani, T.
    Incoronato, P.
    Nacca, V.
    Paragliola, F.
    Napolitano, R.
    Suarato, G.
    Nicastro, A.
    Perrone, A.
    ANNALS OF ONCOLOGY, 2022, 33 : S295 - S295
  • [6] Efficacy and safety of trifluridine/tipiracil plus bevacizumab versus trifluridine/tipiracil monotherapy for refractory metastatic colorectal cancer: A retrospective study
    Li, Rongrong
    Zhou, Hui-Jun
    Zeng, De-Yu
    Jiang, Shao-Feng
    Liu, Wu
    Liu, Zhen-yang
    JOURNAL OF CLINICAL ONCOLOGY, 2023, 41 (16)
  • [7] Efficacy and safety of trifluridine/tipiracil plus bevacizumab versus trifluridine/tipiracil monotherapy for refractory metastatic colorectal cancer: a retrospective cohort study
    Li, Rong-Rong
    Zhou, Hui-Jun
    Zeng, De-Yu
    Jiang, Shao-Feng
    Liu, Wu
    Fruehling, Petter
    Liu, Zhen-Yang
    JOURNAL OF GASTROINTESTINAL ONCOLOGY, 2024, 15 (02) : 612 - 629
  • [8] Efficacy and safety of trifluridine/tipiracil and bevacizumab (FTD/TPI plus BEV) in patients with metastatic colorectal cancer (mCRC) in real-world practice.
    Lago, Nieves Martinez
    Reboredo, Margarita
    Gonzalez Gomez, Borja
    de Frutos Gonzalez, Belen
    Riesco Martinez, Maria Carmen
    Antonilli, Paula Carla
    Lopez Alfonso, Ana
    Gallardo Martin, Elena
    Fernandez Montes, Ana Fernandez
    Cabezon-Gutierrez, Luis
    Castineira, Antia Cousillas
    Ferreiro, Reyes
    JOURNAL OF CLINICAL ONCOLOGY, 2025, 43 (4_SUPPL) : 204 - 204
  • [9] Safety and efficacy of trifluridine/tipiracil plus bevacizumab in RAS mutated patients with metastatic colorectal cancer
    Michalaki, Vasiliki
    Theodosopoulos, Thedosios
    Vezakis, Antonios
    Papaconstantinou, Ioannis
    Kontis, Ioannis
    Dafnios, Nikolaos
    Frangoulidis, George
    Karandrea, Despina
    Papadimitriou, Christos
    JOURNAL OF CLINICAL ONCOLOGY, 2023, 41 (16)
  • [10] Trifluridine-tipiracil plus bevacizumab in refractory metastatic colorectal cancer
    Tasseau, Clara
    Gallois, Claire
    BULLETIN DU CANCER, 2024, 111 (12) : 1087 - 1088
12345